Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Galunisertib - Eli Lilly and Company

Next Previous
Drug Profile

Galunisertib - Eli Lilly and Company

Alternative Names: LY-2157299

Latest Information Update: 24 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer AstraZeneca; Eli Lilly and Company; National Cancer Institute (USA); University of Oklahoma; Vanderbilt-Ingram Cancer Center; Weill Cornell Medical College
  • Class Antineoplastics; Pyrazoles; Pyridines; Pyrroles; Quinolines; Small molecules
  • Mechanism of Action Phosphotransferase inhibitors; Transforming growth factor beta1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Cancer; Colorectal cancer; Glioblastoma; Glioma; Liver cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Rectal cancer; Sarcoma; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 02 Jun 2026 Efficacy and adverse event data from a phase II trial in Prostate cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 07 Jan 2026 Gipfel Life Sciences plans a phase IIa trial for Amyotrophic lateral sclerosis (Combination therapy) in June 2026 (NCT07321860)
  • 10 Oct 2024 Eli Lilly completes a phase II trial in Glioblastoma (Second-line therapy or greater, Recurrent) in the US, Australia, Belgium, Canada, France, Germany, Italy, Poland, Netherlands, Spain (NCT01582269)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top